Literature DB >> 8949570

Insulin treatment normalizes reduced free insulin-like growth factor-I concentrations in diabetic children.

A Bereket1, C H Lang, S L Blethen, L C Ng, T A Wilson.   

Abstract

OBJECTIVE: We have recently demonstrated multiple aberrations in the GH-IGF axis in the sera of children with untreated insulin-dependent diabetes mellitus (IDDM) which were restored after insulin replacement. However, the net result of these alterations in the IGF system on the concentrations of free/biologically available IGF-I in the serum have not been examined directly in diabetic children. In the present study, the effect of diabetes and subsequent insulin replacement on the circulating free IGF-I concentrations are assessed.
DESIGN: Fasting venous serum samples were obtained longitudinally, before and at various times after the initiation of insulin treatment in untreated diabetic subjects.
SUBJECTS: Ten prepubertal, aged (mean +/- SEM) 6.3 +/- 1.0 years, and six adolescent, aged 12.7 +/- 1.1 years, subjects with newly diagnosed and untreated IDDM, and age and pubertal status-matched control children and adolescents were recruited.
METHODS: The serum samples were collected before initiating insulin treatment and 12-24 h, 1 week, and 1 month thereafter in subjects with IDDM. Insulin doses ranged from 0.5 to 1.2 U/kg/day. MEASUREMENTS: Free IGF-I concentration was assayed by a recently developed two-site immunoradiometric assay. Total IGF-I was measured by radioimmunoassay after acid-ethanol extraction of binding proteins. Differences in free and total IGF-I concentrations in IDDM subjects before and during insulin treatment were analysed by repeated measures analysis of variance followed by pairwise multiple comparisons test. In seven subjects with IDDM, where serum IGFBP-1 and IGFBP-3 concentrations, and IGFBP-3 protease activity had also been measured in a previous study, the relationship between these variables and circulating free IGF-I concentrations were examined by linear regression analysis.
RESULTS: Free IGF-I concentrations in prepubertal subjects with IDDM were 0.9 +/- 0.2, 1.5 +/- 0.3, 1.6 +/- 0.3 and 2.5 +/- 0.4 micrograms/l before, 1 day, 1 week and 1 month after insulin treatment, respectively. Free IGF-I concentrations of control prepubertal children were 2.6 +/- 0.5 micrograms/l. Pubertal subjects had higher free IGF-I concentrations than prepubertal subjects but demonstrated a similar type of pattern; before insulin 2.3 +/- 1.1, 1 day 3.8 +/- 1.3, 1 week 3.7 +/- 0.6, 1 month 6.5 +/- 1.5 vs pubertal controls 7.7 +/- 2.0 micrograms/l. Total IGF-I concentrations were also reduced in untreated diabetic subjects and showed a slower pattern of normalization than free IGF-I concentrations. Free IGF-I concentrations correlated positively with total IGF-I and negatively with IGFBP-1 concentrations. There was no significant correlation between free IGF-I and either serum IGFBP-3 concentrations or IGFBP-3 protease activity.
CONCLUSION: Alterations in the IGF system during untreated IDDM lead to a reduction in circulating free IGF-I concentrations which is restored progressively during insulin treatment. An increase in free IGF-I precedes that of total IGF-I suggesting that the former is a more sensitive indicator of the metabolic status. An inverse correlation between free IGF-I and IGFBP-1 supports the hypothesis that IGFBP-1 plays an important role in the acute modulation of free IGF-I levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8949570     DOI: 10.1046/j.1365-2265.1996.7760786.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  9 in total

Review 1.  Growth in patients with type 1 diabetes.

Authors:  Deborah M Mitchell
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

Review 2.  Skeletal growth and bone mineral acquisition in type 1 diabetic children; abnormalities of the GH/IGF-1 axis.

Authors:  Manish Raisingani; Brar Preneet; Brenda Kohn; Shoshana Yakar
Journal:  Growth Horm IGF Res       Date:  2017-04-28       Impact factor: 2.372

3.  Sugar and bone: a not-so sweet story.

Authors:  Clifford J Rosen
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

4.  Insulin-like growth factor 1 rescues R28 retinal neurons from apoptotic death through ERK-mediated BimEL phosphorylation independent of Akt.

Authors:  Dejuan Kong; Lijie Gong; Edith Arnold; Sumathi Shanmugam; Patrice E Fort; Thomas W Gardner; Steven F Abcouwer
Journal:  Exp Eye Res       Date:  2016-08-07       Impact factor: 3.467

5.  Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.

Authors:  A Gualberto; M L Hixon; D D Karp; D Li; S Green; M Dolled-Filhart; L G Paz-Ares; S Novello; J Blakely; C J Langer; M N Pollak
Journal:  Br J Cancer       Date:  2010-11-23       Impact factor: 7.640

Review 6.  O-GlcNAcylation: a bridge between glucose and cell differentiation.

Authors:  Chao Sun; Jin Shang; Yuan Yao; Xiaohong Yin; Minghan Liu; Huan Liu; Yue Zhou
Journal:  J Cell Mol Med       Date:  2016-03-01       Impact factor: 5.310

Review 7.  Linear Growth in Children and Adolescents with Type 1 Diabetes Mellitus.

Authors:  Elisa Santi; Giorgia Tascini; Giada Toni; Maria Giulia Berioli; Susanna Esposito
Journal:  Int J Environ Res Public Health       Date:  2019-09-30       Impact factor: 3.390

Review 8.  Growth abnormalities in children with type 1 diabetes, juvenile chronic arthritis, and asthma.

Authors:  Cosimo Giannini; Angelika Mohn; Francesco Chiarelli
Journal:  Int J Endocrinol       Date:  2014-02-04       Impact factor: 3.257

9.  Insulin-Like Growth Factor-1 at Diagnosis and during Subsequent Years in Adolescents with Type 1 Diabetes.

Authors:  Simona I Chisalita; J Ludvigsson
Journal:  J Diabetes Res       Date:  2018-03-20       Impact factor: 4.011

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.